High dose flupenthixol decanoate in chronic schizophrenia.

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Medicine

Background:

• Chronic schizophrenia is a debilitating mental disorder.
• Drug resistance is a significant challenge in schizophrenia treatment.
• Flupenthixol decanoate is a long-acting antipsychotic used for schizophrenia.

Purpose of the Study:

• To compare the efficacy and safety of high-dose versus standard-dose flupenthixol decanoate in female chronic schizophrenic patients.
• To investigate the relationship between plasma flupenthixol levels and treatment outcomes.
• To identify potential predictors of treatment response.

Main Methods:

• A 13-week, double-blind, randomized controlled trial.
• Inclusion of female in-patients with chronic, drug-resistant schizophrenia.
• Administration of high-dose or standard-dose flupenthixol decanoate.
• Monitoring of plasma flupenthixol levels, mental state, ward behavior, and extrapyramidal side-effects.

Main Results:

• Plasma flupenthixol levels varied five-fold between individuals, higher in the high-dose group.
• No significant differences in overall mental state, ward behavior, or side-effects between dose groups.
• High-dose group showed significant worsening of extrapyramidal side-effects.
• Standard-dose group showed significant decrease in social withdrawal.
• A subgroup with potential pharmacokinetic resistance improved mentally on the high dose.

Conclusions:

• High-dose flupenthixol decanoate did not offer superior overall efficacy compared to standard dose in this patient population.
• Pharmacokinetic factors may influence treatment response in some patients with chronic schizophrenia.
• Further research is needed to optimize dosing strategies and identify responders.